ODI Pharma (ODI) Q1 25/26 earnings summary

Executive summary

• Entered new fiscal year with improved commercial environment and operational stability, especially in Poland.

• Substantial increase in order volumes and net sales, reflecting normalization of regulatory and logistics conditions.

• Strategic partnerships and product approvals have enabled broad access to pharmacies and patients.

Financial highlights

• Net sales for Q1 2025/26 reached SEK 5,968,143, up from SEK 143,793 year-over-year.

• Operating income for the quarter was SEK 111,917, compared to a loss of SEK -1,340,003 in the prior year.

• Net loss after financial items was SEK -37,027, a significant improvement from SEK -1,468,183 year-over-year.

• Earnings per share were SEK -0.00, compared to SEK -0.10 in the same quarter last year.

• Cash flow from operations was SEK 75,910, compared to SEK -1,241,119 in the previous year.

Outlook and guidance

• Net sales are expected to further increase in coming quarters, with continued focus on growth in regulated European medical cannabis markets.

• Emphasis remains on sustainable value creation through a capital-efficient, partner-led model.